RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer.


Journal

Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030

Informations de publication

Date de publication:
16 01 2020
Historique:
received: 28 06 2019
revised: 07 11 2019
accepted: 06 12 2019
pubmed: 31 12 2019
medline: 16 3 2021
entrez: 30 12 2019
Statut: ppublish

Résumé

RUVBL1 and RUVBL2 (collectively RUVBL1/2) are essential AAA+ ATPases that function as co-chaperones and have been implicated in cancer. Here we investigated the molecular and phenotypic role of RUVBL1/2 ATPase activity in non-small cell lung cancer (NSCLC). We find that RUVBL1/2 are overexpressed in NSCLC patient tumors, with high expression associated with poor survival. Utilizing a specific inhibitor of RUVBL1/2 ATPase activity, we show that RUVBL1/2 ATPase activity is necessary for the maturation or dissociation of the PAQosome, a large RUVBL1/2-dependent multiprotein complex. We also show that RUVBL1/2 have roles in DNA replication, as inhibition of its ATPase activity can cause S-phase arrest, which culminates in cancer cell death via replication catastrophe. While in vivo pharmacological inhibition of RUVBL1/2 results in modest antitumor activity, it synergizes with radiation in NSCLC, but not normal cells, an attractive property for future preclinical development.

Identifiants

pubmed: 31883965
pii: S2451-9456(19)30401-5
doi: 10.1016/j.chembiol.2019.12.005
pmc: PMC8048778
mid: NIHMS1682340
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Carrier Proteins 0
Enzyme Inhibitors 0
Multiprotein Complexes 0
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-
DNA Helicases EC 3.6.4.-
RUVBL1 protein, human EC 3.6.4.12
RUVBL2 protein, human EC 3.6.4.12

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-121.e14

Subventions

Organisme : NCI NIH HHS
ID : R01 CA124633
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM127390
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA223828
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Nat Methods. 2007 Mar;4(3):207-14
pubmed: 17327847
Cell. 2004 Dec 17;119(6):767-75
pubmed: 15607974
Nat Methods. 2007 Apr;4(4):337-44
pubmed: 17351622
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
Curr Biol. 2014 Sep 22;24(18):2097-2110
pubmed: 25176633
Nat Protoc. 2012 Mar 01;7(3):594-605
pubmed: 22383038
Nature. 2004 Dec 23;432(7020):1036-40
pubmed: 15616564
Bioinformatics. 2004 Jun 12;20(9):1466-7
pubmed: 14976030
Nat Rev Urol. 2013 Aug;10(8):483-7
pubmed: 23752995
J Am Assoc Lab Anim Sci. 2010 May;49(3):329-34
pubmed: 20587165
Genome Res. 2004 Jun;14(6):1085-94
pubmed: 15173114
Mol Cell. 2004 Nov 5;16(3):465-77
pubmed: 15525518
Structure. 2015 Mar 3;23(3):483-495
pubmed: 25661652
Nucleic Acids Res. 2014 Dec 16;42(22):13736-48
pubmed: 25428364
J Biol Chem. 1998 Oct 23;273(43):27786-93
pubmed: 9774387
J Biol Chem. 2004 May 7;279(19):20067-75
pubmed: 14982920
J Biol Chem. 2018 Aug 17;293(33):12855-12861
pubmed: 29959228
PLoS One. 2015 Jul 22;10(7):e0133576
pubmed: 26201077
Mol Cell. 2017 Jan 5;65(1):105-116
pubmed: 27989442
Science. 2003 Jun 6;300(5625):1542-8
pubmed: 12791985
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
EMBO J. 2015 Sep 14;34(18):2363-82
pubmed: 26303906
Nat Struct Mol Biol. 2011 Jun;18(6):721-7
pubmed: 21552262
Trends Biochem Sci. 2018 Jan;43(1):4-9
pubmed: 29203338
Leukemia. 2013 Jul;27(7):1461-8
pubmed: 23403462
Mol Cell. 2015 Sep 17;59(6):998-1010
pubmed: 26365379
Hepatology. 2007 Oct;46(4):1108-18
pubmed: 17657734
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
ACS Chem Biol. 2019 Feb 15;14(2):236-244
pubmed: 30640450
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mol Cancer Res. 2013 Feb;11(2):133-9
pubmed: 23233483
Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1788-1800
pubmed: 28341484
Tumour Biol. 2016 Oct 10;:
pubmed: 27722820
Mol Cell Biol. 2009 Sep;29(18):4971-81
pubmed: 19620283
Sci Adv. 2019 May 01;5(5):eaaw1616
pubmed: 31049401
Cancer Cell Int. 2007 Sep 24;7:15
pubmed: 17892593
Sci Signal. 2010 Apr 06;3(116):ra27
pubmed: 20371770
Nucleic Acids Res. 2012 Nov;40(21):11086-99
pubmed: 23002137
Cell. 2000 Aug 18;102(4):463-73
pubmed: 10966108
Biochem Biophys Res Commun. 2018 Apr 15;498(4):932-939
pubmed: 29545175
J Proteome Res. 2012 Dec 7;11(12):6282-90
pubmed: 23088505
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Proteomics. 2011 Jul;11(14):2790-7
pubmed: 21656681
J Biol Chem. 2007 Sep 7;282(36):26132-9
pubmed: 17617668
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Cancer Discov. 2016 Aug;6(8):900-13
pubmed: 27260157
Nat Rev Cancer. 2010 Aug;10(8):537-49
pubmed: 20651736
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9942-7
pubmed: 12096193
Hum Pathol. 2007 Jul;38(7):978-985
pubmed: 17442372
J Proteome Res. 2004 Sep-Oct;3(5):958-64
pubmed: 15473683
Nucleic Acids Res. 2015 Oct 15;43(18):8973-89
pubmed: 26275778
Mol Cell Biol. 2013 Mar;33(6):1164-74
pubmed: 23297341
Leukemia. 2014 Jun;28(6):1271-9
pubmed: 24342949
Annu Rev Biophys. 2014;43:257-78
pubmed: 24773018
J Mol Biol. 1993 Jul 20;232(2):397-405
pubmed: 8393934
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029

Auteurs

Paul Yenerall (P)

Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA; Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Amit K Das (AK)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Shan Wang (S)

Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Rahul K Kollipara (RK)

Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Long Shan Li (LS)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Pamela Villalobos (P)

Department of Translational Molecular Pathology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Josiah Flaming (J)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Yu-Fen Lin (YF)

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Kenneth Huffman (K)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Brenda C Timmons (BC)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Collin Gilbreath (C)

Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Rajni Sonavane (R)

Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Lisa N Kinch (LN)

Howard Hughes Medical Institute and Departments of Biophysics and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Jaime Rodriguez-Canales (J)

Department of Translational Molecular Pathology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Cesar Moran (C)

Department of Pathology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Carmen Behrens (C)

Department of Thoracic/Head and Neck Medical Oncology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Makoto Hirasawa (M)

Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo 103-8426, Japan.

Takehiko Takata (T)

Oncology Medical Science Department, Medical Affairs, Daiichi-Sankyo Co., Ltd., Tokyo 103-8426, Japan.

Ryo Murakami (R)

Oncology Research Laboratories II, Daiichi-Sankyo Co., Ltd., Tokyo 103-8426, Japan.

Koichi Iwanaga (K)

Oncology Medical Science Department, Medical Affairs, Daiichi-Sankyo Co., Ltd., Tokyo 103-8426, Japan.

Benjamin P C Chen (BPC)

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Nick V Grishin (NV)

Howard Hughes Medical Institute and Departments of Biophysics and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Ganesh V Raj (GV)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Thoracic/Head and Neck Medical Oncology, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.

John D Minna (JD)

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: john.minna@utsouthwestern.edu.

Ralf Kittler (R)

Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ralf.kittler@utsouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH